Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor.

Benzer Materyaller

• Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.
  Yazar:: Guay, D R, ve diğerleri
  Baskı/Yayın Bilgisi: (1986)
• In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens.
  Yazar:: Bowie, W R, ve diğerleri
  Baskı/Yayın Bilgisi: (1986)
• Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
  Yazar:: Cappelletty, D M, ve diğerleri
  Baskı/Yayın Bilgisi: (1996)
• Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora.
  Yazar:: Iravani, A, ve diğerleri
  Baskı/Yayın Bilgisi: (1986)
• Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid.
  Yazar:: Barry, A L, ve diğerleri
  Baskı/Yayın Bilgisi: (1993)